Amino acid substitutions at position 28 of NS5A in HCV genotype 1a (GT1a) represent a major resistance pathway to ledipasvir (LDV), ombitasvir (OBV) and daclatasvir (DCV). GT1a and GT1b viruses are polymorphic at position 28: methionine (M) is most common in GT1a whereas leucine (L) predominates in GT1b. To investigate the impact of amino acid 28 polymorphisms on NS5A drug susceptibility, we evaluated replicons containing M28 or L28 substitutions alone and in combination with NS5A drug resistance associated mutations (RAMs) at positions 30, 31 and 93.
A panel of replicons containing M28 or L28 substitutions alone, and in combination with RAMs at positions 30, 31 and 93 was constructed using H77 (GT1a) and Con1 (GT1b) NS5A sequences. NS5A drug susceptibility (fold change in IC50, FC) relative to the parental reference replicon was determined using a luciferase-reporter replicon assay.
The introduction of an L28M substitution to the GT1b NS5A sequence conferred subtle or no reductions in susceptibility to LDV, OBV and DCV (FC=1.0 to 2.5). L28M in combination with one additional NS5A RAM notably reduced susceptibility relative to the RAM alone: L28M+L31M vs. L31M (FC: LDV=165, 4.5; OBV=2.4, 0.9; DCV=6.7, 1.5), L28M+Y93H vs. Y93H (FC: LDV=12597, 368; OBV=1371, 125; DCV=188, 8). The introduction of an M28L substitution to the GT1a NS5A sequence subtly increases susceptibility to LDV, OBV and DCV (FC=0.2 to 0.8). M28L in combination with one additional RAM notably increased susceptibility compared to the RAM alone: M28L+Q30R vs. Q30R (FC: LDV=1.4, 477; OBV=14, 4115; DCV=1.2, 298), M28L+Q30H vs. Q30H (FC: LDV=0.7, 269; OBV=0.5, 4.8; DCV=1.3, 567), M28L+L31M vs. L31M (FC: LDV=2.1, 187; OBV=0.4, 2.3; DCV=1.4, 132), M28L+Y93H vs. Y93H (FC: LDV=250, 813; OBV=1770, 47582; DCV=74, 1059).
This study demonstrated that the M/L polymorphism at position 28 of NS5A differentially impacts the susceptibility of HCV GT1a and GT1b to NS5A inhibitors. The introduction of RAMs at positions 30, 31 or 93 conferred larger reductions in NS5A drug susceptibility in the context of the M28 substitution in GT1a compared to the L28 substitution in GT1b. These findings explain, in part, why GT1a viruses containing NS5A RAMs display larger reductions in NS5A drug susceptibility versus comparable GT1b viruses, which in turn may explain the less favorable treatment responses of GT1a HCV infected individuals treated with NS5A inhibitors.